XML 36 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Statements of Cash Flows (USD $)
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Operating activities:      
Net loss $ (76,367,000)us-gaap_NetIncomeLoss $ (55,283,000)us-gaap_NetIncomeLoss $ (23,348,000)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used for operating activities:      
Stock-based compensation 8,067,000us-gaap_ShareBasedCompensation 10,890,000us-gaap_ShareBasedCompensation 5,732,000us-gaap_ShareBasedCompensation
Depreciation and amortization 578,000us-gaap_DepreciationAndAmortization 333,000us-gaap_DepreciationAndAmortization 197,000us-gaap_DepreciationAndAmortization
Amortization of debt discount 573,000us-gaap_AmortizationOfDebtDiscountPremium 533,000us-gaap_AmortizationOfDebtDiscountPremium 389,000us-gaap_AmortizationOfDebtDiscountPremium
Gain from discontinued operations     (1,082,000)us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
Impairment loss on property and equipment 905,000us-gaap_AssetImpairmentCharges    
Loss on disposal of property and equipment 17,000us-gaap_GainLossOnSaleOfPropertyPlantEquipment    
Change in operating assets and liabilities:      
Prepaid expense and other current assets (419,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (54,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (318,000)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accounts payable 1,285,000us-gaap_IncreaseDecreaseInAccountsPayable (426,000)us-gaap_IncreaseDecreaseInAccountsPayable 984,000us-gaap_IncreaseDecreaseInAccountsPayable
Accrued clinical liabilities 2,038,000hrtx_IncreaseDecreaseInClinicalLiabilities 1,127,000hrtx_IncreaseDecreaseInClinicalLiabilities 92,000hrtx_IncreaseDecreaseInClinicalLiabilities
Accrued payroll and employee liabilities 165,000us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities 2,153,000us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities (149,000)us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities
Other accrued liabilities 2,876,000us-gaap_IncreaseDecreaseInOtherAccruedLiabilities (36,000)us-gaap_IncreaseDecreaseInOtherAccruedLiabilities 494,000us-gaap_IncreaseDecreaseInOtherAccruedLiabilities
Net cash used for operating activities (60,282,000)us-gaap_NetCashProvidedByUsedInOperatingActivities (40,763,000)us-gaap_NetCashProvidedByUsedInOperatingActivities (17,009,000)us-gaap_NetCashProvidedByUsedInOperatingActivities
Investing activities:      
Purchases of property and equipment (1,438,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (1,685,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (972,000)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash used for investing activities (1,438,000)us-gaap_NetCashProvidedByUsedInInvestingActivities (1,685,000)us-gaap_NetCashProvidedByUsedInInvestingActivities (972,000)us-gaap_NetCashProvidedByUsedInInvestingActivities
Financing activities:      
Net proceeds from sale of common stock and/or pre-funded warrants 58,916,000us-gaap_ProceedsFromIssuanceOfCommonStock 57,802,000us-gaap_ProceedsFromIssuanceOfCommonStock 50,491,000us-gaap_ProceedsFromIssuanceOfCommonStock
Proceeds from purchases under the Employee Stock Purchase Plan 91,000us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans 34,000us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans 22,000us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
Proceeds from stock option exercises 3,101,000us-gaap_ProceedsFromStockOptionsExercised 2,793,000us-gaap_ProceedsFromStockOptionsExercised  
Proceeds from warrant exercises   600,000us-gaap_ProceedsFromWarrantExercises  
Net proceeds from convertible note financing     3,000,000us-gaap_ProceedsFromConvertibleDebt
Net cash provided by financing activities 62,108,000us-gaap_NetCashProvidedByUsedInFinancingActivities 61,229,000us-gaap_NetCashProvidedByUsedInFinancingActivities 53,513,000us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase in cash and cash equivalents 388,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 18,781,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 35,532,000us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of year 72,287,000us-gaap_CashAndCashEquivalentsAtCarryingValue 53,506,000us-gaap_CashAndCashEquivalentsAtCarryingValue 17,974,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of year 72,675,000us-gaap_CashAndCashEquivalentsAtCarryingValue 72,287,000us-gaap_CashAndCashEquivalentsAtCarryingValue 53,506,000us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash flow information:      
Interest paid $ 0us-gaap_InterestPaid $ 0us-gaap_InterestPaid $ 0us-gaap_InterestPaid